MedTrace Logo

Surefire Institutional DEB-TACE

NCT03211598 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-01-22

No results posted yet for this study

Summary

The purpose of this study is to determine the feasibility and safety of the Surefire Infusion System (SIS) for delivery of Drug Eluting Beads Transcatheter Chemoembolization (DEB-TACE) in the HCC population. This study will allow us to determine the effectiveness of SIS for HCC in terms of disease response.

Conditions

Interventions

PROCEDURE

TACE with Surefire

Subjects that consent to the study will receive their TACE procedure through the Surefire Infusion System

Sponsors & Collaborators

  • Surefire Medical, Inc.

    collaborator INDUSTRY

  • Alexander Kim

    lead OTHER

Principal Investigators

  • Alexander Y Kim, MD · MedStar Georgetown University Hospital

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2020-04-30
Completion
2020-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03211598 on ClinicalTrials.gov